Search

Your search keyword '"Neoplasm Metastasi"' showing total 3 results
Start Over Descriptor "Neoplasm Metastasi" Publisher springer nature
3 results on '"Neoplasm Metastasi"'

1. Sirolimus inhibits the growth and metastatic progression of hepatocellular carcinoma.

Author

Zheng Wang, Jian Zhou, Jia Fan, Chang-Jun Tan, Shuang-Jian Qiu, Yao Yu, Xiao-Wu Huang, and Zhao-You Tang

Subjects
*RAPAMYCIN, *IMMUNOSUPPRESSIVE agents, *TRANSPLANTATION of organs, tissues, etc., *LIVER cancer, *CANCER invasiveness, *CANCER patients, *TUMOR growth
Abstract

Immunosuppressive therapy after liver transplantation for hepatocellular carcinoma (HCC) is one of the major contributory factors for HCC recurrence and metastasis. Sirolimus, a potent immunosuppressant, has been reported to be an effective inhibitor in a variety of tumors. The present study is designed to explore whether sirolimus could block the growth and metastatic progression of HCC. MHCC97H cells were used as targets to explore the effect of sirolimus on cell cycle progression, apoptosis, proliferation, and its antiangiogenic mechanism. LCI-D20, a highly metastatic model of human HCC in nude mice, was also used as the model tumor to explore the effect of sirolimus on tumor growth and metastatic progression. In vitro, sirolimus induced cell cycle arrest at the G1 checkpoint and blocked proliferation of MHCC97H cells but did not induce apoptosis. In vivo, sirolimus prevented tumor growth and metastatic progression in LCI-D20. Intratumoral microvessel density and circulating levels of VEGF in tumor-bearing mice were also significantly reduced in sirolimus treatment group. Quantitative RT-PCR showed that sirolimus down-regulated the mRNA expression of VEGF and HIF-1a, but not of bFGF, and TGF-b in MHCC97H cells. Furthermore, western blot analysis confirmed that sirolimus also decreased expression of HIF-1a at protein level, in parallel with the down-regulation of the levels of VEGF protein excretion in a time-dependent manner as compared to untreated control cells following anoxia. The immunosuppressive macrolide sirolimus prevents the growth and metastatic progression of HCC, and suppresses VEGF synthesis and secretion by downregulating HIF-1a expression. Sirolimus may be useful for clinical application in patients who received a liver transplant for HCC. [ABSTRACT FROM AUTHOR]

Published
2009
Full Text
View/download PDF

2. Tumor characteristics and prognosis in familial breast cancer

Author

Matilde Pensabene, Rossella Lauria, Mario Giuliano, Anna Crispo, Ivana Cerillo, Valeria Forestieri, C. De Angelis, Grazia Arpino, Maurizio Montella, S. De Placido, Raffaella Ruocco, Caterina Condello, Arpino, Grazia, Pensabene, Matilde, Condello, C., Ruocco, Raffaella, Cerillo, Ivana, Lauria, Rossella, Forestieri, Valeria, Giuliano, Mario, DE ANGELIS, Carmine, Montella, M., Crispo, Anna, and DE PLACIDO, Sabino

Subjects
0301 basic medicine, Oncology, Cancer Research, endocrine system diseases, medicine.medical_treatment, Genes, BRCA1, Estrogen receptor, 0302 clinical medicine, Surgical oncology, Young adult, Family history, Neoplasm Metastasis, skin and connective tissue diseases, Middle Aged, Prognosis, female genital diseases and pregnancy complications, Tumor Burden, Neoplasm Metastasi, Receptors, Estrogen, 030220 oncology & carcinogenesis, Female, Survival Analysi, Receptors, Progesterone, Breast Neoplasm, Human, Research Article, Adult, medicine.medical_specialty, animal structures, Prognosi, Breast Neoplasms, 03 medical and health sciences, Young Adult, Breast cancer, Genetic, Internal medicine, medicine, Biomarkers, Tumor, Genetics, Humans, Survival analysis, Radical mastectomy, Aged, Neoplasm Staging, business.industry, Cancer, medicine.disease, Survival Analysis, 030104 developmental biology, Mutation, Neoplasm Grading, business
Abstract

BACKGROUND: Approximately 5-10% of breast cancers are hereditary and their biology and prognosis appear to differ from those of sporadic breast cancers. In this study we compared the biological features and clinical characteristics of non metastatic breast cancer in patients with BRCA mutations versus patients with a family history suggesting hereditary breast cancer but without BRCA mutations (BRCA wild type) versus patients with sporadic disease, and correlated these findings with clinical outcome. METHODS: We retrieved the clinical and biological data of 33 BRCA-positive, 66 BRCA-wild type and 1826 sporadic breast cancer patients contained in a single institution clinical database between 1980 and 2012. Specifically, we recorded age, tumor size, nodal status, treatment type, pattern of relapse, second primary incidence, outcome (disease-free survival and overall survival), and biological features (estrogen receptor [ER], progesterone receptor [PgR], tumor grade, proliferation and c-erbB2 status). Median follow-up was 70 months. RESULTS: BRCA-positive patients were significantly younger than sporadic breast cancer patients, and less likely to be ER-, PgR- or c-erbB2-positive than women with BRCA-wild type or sporadic breast cancer. Tumor size and grade, nodal status and proliferation did not differ among the three groups. Rates of radical mastectomy were 58, 42 and 37%, and those of conservative surgery were 42, 58 and 63% in women with BRCA-positive, BRCA-wild type and sporadic breast cancer (p = 0.03), respectively. The incidence of contralateral breast cancer was 12, 14 and 0% (p

Full Text
View/download PDF

3. Does prostate acinar adenocarcinoma with Gleason Score 3 + 3 = 6 have the potential to metastasize?

Author

Matteo Santoni, Alberto Briganti, Francesco Montorsi, Liang Cheng, Antonio Lopez-Beltran, Marina Scarpelli, Roberta Mazzucchelli, Rodolfo Montironi, Montironi, Rodolfo, Scarpelli, Marina, Mazzucchelli, Roberta, Lopez-Beltran, Antonio, Santoni, Matteo, Briganti, Alberto, Montorsi, Francesco, and Cheng, Liang

Subjects
Male, Pathology, medicine.medical_specialty, Histology, Lymphovascular invasion, medicine.medical_treatment, Biopsy, Case Report, Acinar adenocarcinoma, urologic and male genital diseases, Gleason Score 6, Pathology and Forensic Medicine, Prostate cancer, Humans, Medicine, Neoplasm Metastasis, Gleason score, Periprostatic lymph node, Prostate Acinar Adenocarcinoma, Anaplasia, Aged, Lymph node metastasis, business.industry, Prostatectomy, Carcinoma, Acinar Cell, Prostate, Prostatic Neoplasms, Lymph Node, Cell Differentiation, Lymphatic Metastasi, General Medicine, medicine.disease, Extraprostatic, Neoplasm Metastasi, Lymphatic Metastasis, Prostatic Neoplasm, Disease Progression, Adenocarcinoma, Lymph Nodes, Neoplasm Grading, Gleason score 6 adenocarcinoma, business, Human
Abstract

Background There is a worldwide debate involving clinicians, uropathologists as well as patients and their families on whether Gleason score 6 adenocarcinoma should be labelled as cancer. Case description We report a case of man diagnosed with biopsy Gleason score 6 acinar adenocarcinoma and classified as low risk (based on a PSA of 5 ng/mL and stage cT2a) whose radical prostatectomy specimen initially showed organ confined Gleason score 3 + 3 = 6, WHO nuclear grade 3, acinar adenocarcinoma with lymphovascular invasion and secondary deposit in a periprostatic lymph node. When deeper sections were cut to the point that almost all the slice present in the paraffin block was sectioned, a small tumor area (

Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results